Telapristone acetate

DB05253InvestigationalSmall molecule

Telapristone acetate, an orally-available, selective progesterone receptor modulator, is in development to alleviate symptoms associated with both uterine fibroids and endometriosis.

Mechanism: Proellex selectively blocks the progesterone receptor thus avoiding the adverse effects of GnRH agonists associated with the induction of a low estrogen, menopausal-like state in women.
Curator reviewed
Primary indication: For the treatment of uterine fibroids and endometriosis.Curator reviewed
Formula / weight: C₃₁H₃₉NO₅ · 505.655 g/mol (avg)
Code names: CDB-4124 · RU 44675

Resolves to

Compound

UNII1K9EYK92PQCAS198414-31-2ChEMBLCHEMBL2105694

Structure

InChIKeyJVBGZFRPTRKSBB-MJBQOYBXSA-NSMILES[H][C@@]12CC[C@](OC(C)=O)(C(=O)COC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]

Targets

P06401PGR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

22Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Telapristone acetate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account